Cytokinetics, Incorporated ( CYTK) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytokinetics, Incorporated ( CYTK)

CYTK 64.12

+1.3%

Dec 24 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	7/17/2013 7:17:15 PM
	of 405

fwiw: Leerink Swann Starts Cytokinetics (CYTK) at Outperform 7:13 AM 7/17/2013 - StreetInsider (Updated - July 17, 201311:05 AM EDT) Leerink Swann initiated coverage on Cytokinetics (NASDAQ: CYTK) with an Outperform rating and a price target of $20.00. Analyst Joseph P. Schwartz thinks commercial potential of the Cytokinetics approach has been validated by its agreement with Amgen (Nasdaq: AMGN). "CYTK has two lead products in development that via novel mechanisms of action appear likely to deliver a therapeutic benefit to patients afflicted by Amyotrophilc Lateral Sclerosis (ALS) and Heart Failure (HF), 2 areas of significant unmet medical need. We are bullish ahead of Phase II data at YE for lead product tirasemtiv, which MEDACorp Key Opinion Leaders (KOL) believe could be the 1st approved therapeutic able to ameliorate the harsh symptoms of ALS. Nearer term, we anticipate that upcoming Phase II Acute HF data for AMGN-partnered product omecamtiv mecarbil will likely justify advancement of the program and initiation of Phase III in '14." For an analyst ratings summary and ratings history on Cytokinetics (NASDAQ: CYTK)click here. For more ratings news on Cytokinetics click here. Shares of Cytokinetics closed at $13.70 yesterday, with a 52 week range of $0.58-$14.28.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next